2024-03-18-世界卫生组织-Highlights_from_the_Meeting_of_the_Strategic_Advisory_Group_of_Experts_SAGE_on_Immunization,_11-13_March_2024_5页_147kb

报告摘要

Reflected on the 50th anniversary of the Expanded Programme on Immunization (EPI), highlighting its role in child survival, disease control, and primary healthcare equity.
Celebrated innovations in vaccines, including new technologies and enhanced manufacturing in emerging economies, but noted setbacks in IA2030 goals.
-Recommended adherence to the four core principles of IA2030 (country-owned, people-centred, partnership-based, data-guided) and emphasized global health security through vaccine use.

Provided $290 million for COVID-19 catch-up vaccinations and supported new vaccines like those for malaria and HPV.
Outlined an ambitious Gavi 6.0 strategy for 2025-30, focusing on health security and simplified processes for VPD prevention.

Most regions experienced COVID-19 disruptions, with varied recovery; challenges include identifying missed vaccinations and monitoring older children.
Encouraged flexible programs in fragile settings and noted successful country initiatives, stressing the need for robust data systems and community engagement.

Discussed the Immunization Agenda 2030 (IA2030) "Big Catch-Up," emphasizing political will, health worker capacity, and data monitoring for accountability.
Addressed gaps in immunization data systems and called for long-term investments in digital solutions and evaluating catch-up vaccination impacts.

Noted WPV1 containment but concerns over circulating vaccine-derived poliovirus (cVDPV) in Africa; recommended improving routine polio coverage and transitioning to IPV-only schedules in low-risk countries.
Suggested intradermal or intramuscular routes for off-label IPV fractional dosing in outbreak response.

Recommended hepatitis E vaccination for women of childbearing age in fragile settings, overriding potential risks; advised on off-label 2-dose schedules and urged research for pregnant women, HIV-positive individuals, and youth.

COVID-19 trends remain declining; SAGE supported booster doses of Omicron-adapted vaccines but acknowledged barriers like inequity.
Reiterated priority-use groups and vaccine recommendations based on WHO guidelines, noting monovalent XBB vaccines' effectiveness.

Reviewed mpox epidemiology, highlighting persistence in Africa; updated vaccination recommendations for outbreak and non-outbreak settings.
Called for greater research and equitable access in endemic regions.

Discussed challenges in vaccine clinical trials, particularly for group B streptococcus and chikungunya, advocating for immune correlate approvals where data support them, to avoid delays in LMICs.
Requested WHO review of chikungunya vaccine evidence and usage scenarios.

Summarized recent RSV vaccine approvals, showing high efficacy in preventing disease; SAGE prioritized these for review and addressed safety concerns like preterm birth risks.
A working group is reviewing products for infants and adults, with findings due in 2024.

展开完整摘要